| Overview |
| bs-23029R |
| DNMT-3 alpha Polyclonal Antibody |
| WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human |
| Dog, Cow, Sheep, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DNMT-3 alpha |
| 51-150/912 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 1788 |
| Q9Y6K1 |
| Cytoplasm, Nucleus |
| DNA (cytosine 5 ) methyltransferase 3 alpha; DNA (cytosine 5) methyltransferase 3A; DNA cytosine methyltransferase 3A2; DNA methyltransferase 3a; DNA methyltransferase HsaIIIA; DNA MTase HsaI; DNA MTase HsaIIIA; DNMT 3a; DNMT; Dnmt3a; DNMT3A2; M HsaIIIA; M.HsaIIIA; MCMT; Methyl CpG binding domain protein 3a. |
| The tumor organization has the DNA methylation disorder, including and damps cancer gene high methylation DNA with the cell multiplication cycle close related cancer gene low methylation the methyl transferase (Dnmt) participation methylation the formation (is mainly Dnmt3a and Dnmt3b) and the maintenance (is mainly Dnmt1) (isoform CRA_b) (DNA methyltransferase MmuIIIA) (DNA MTase MmuIIIA) |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz